CoChat

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

Pivonello, Rosario, Petersenn, Stephan, Newell‐Price, John, Findling, James W., Gu, Feng, Maldonado, Mario, Trovato, Andrew, Hughes, Gareth, Salgado, Luiz R., Lacroix, André, Schopohl, Jochen, Biller, Beverly M.K., Pasireotide B2305 Study Group · 2014 · Clinical Endocrinology
Cited by 117

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Summary: Objective: Signs and symptoms of Cushing's disease are associated with high burden of illness. In this analysis, we evaluated the effect of pasireotide treatment on signs and symptoms in patients with Cushing's disease. Design: Phase III study with double‐blind randomization of two pasireotide doses. Methods: Patients (n = 162) with persistent/recurrent or de novo Cushing's disease and urinary free cortisol (UFC) levels ≥1·5× upper limit of normal (ULN) were randomized to receive subcutaneous pasireotide (600/900 μg bid). At month 3, patients with UFC ≤2 × ULN and not exceeding the baseline value continued their randomized dose; all others received 300 μg bid uptitration. At month 6, patients could enter an open‐label phase until month 12 with a maximal dose of 1200 μg bid. Changes in signs and symptoms of hypercortisolism over 12 months' treatment in patients still enroled in the study and with evaluable measurements were assessed in relation to degree of UFC control. Results: Reductions in blood pressure were observed even without full UFC control and were greatest in patients who did not receive antihypertensive medications during the study. Significant reductions in total cholesterol and low‐density lipoprotein (LDL)‐cholesterol were observed in patients who achieved UFC control. Reductions in BMI, weight and waist circumference occurred during the study even without full UFC control. Adverse effects were typical of somatostatin analogues except for hyperglycaemia‐related events, which were experienced by 72·8% of patients. Conclusions: In the largest Phase III study of medical therapy in Cushing's disease, significant improvements in signs and symptoms were seen during 12 months of pasireotide treatment, as UFC levels decreased.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.12431

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 117

Metadata

Authors
Pivonello, R., Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Trovato, A., Hughes, G., Salgado, L. R., Lacroix, A., Schopohl, J., Biller, B. M. K., & Pasireotide B2305 Study Group
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2014-03-27
Volume
81
Issue
3
Pages
408-417
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2017088119
Cited by
117
References
12
FWCI
11.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. https://app.cochat.ai/papers/10.1111/cen.12431
The paper
Pivonello, R., Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Trovato, A., Hughes, G., Salgado, L. R., Lacroix, A., Schopohl, J., Biller, B. M. K., & Pasireotide B2305 Study Group. (2014). Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clinical Endocrinology. https://doi.org/10.1111/cen.12431

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.